Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration

Maya Kishi; Akiko Miki; Aya Kamimura; Mina Okuda; Wataru Matsumiya; Hisanori Imai; Sentaro Kusuhara; Makoto Nakamura

doi:10.3390/jcm12155145

Journal of Clinical Medicine (Aug 2023)

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration

Maya Kishi,
Akiko Miki,
Aya Kamimura,
Mina Okuda,
Wataru Matsumiya,
Hisanori Imai,
Sentaro Kusuhara,
Makoto Nakamura

Affiliations

Maya Kishi: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Akiko Miki: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Aya Kamimura: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Mina Okuda: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Wataru Matsumiya: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Hisanori Imai: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Sentaro Kusuhara: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Makoto Nakamura: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan

DOI: https://doi.org/10.3390/jcm12155145
Journal volume & issue: Vol. 12, no. 15
p. 5145

Abstract

Read online

To evaluate the functional and anatomical effects of switching to faricimab for patients with neovascular age-related macular degeneration (nAMD) refractory to intravitreal aflibercept, this retrospective study evaluated patients with nAMD who received intravitreal injections of aflibercept (IVA) every p p p < 0.01). An ocular adverse event (retinal pigment epithelium tear) developed in one eye. Switching to faricimab was effective for anatomic changes. It may be an additional treatment option for some eyes refractory to IVA.

Published in Journal of Clinical Medicine

ISSN: 2077-0383 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine
Website: http://www.mdpi.com/journal/jcm

About the journal

Abstract

Keywords